Validation of the Liver Disease Quality of Life Instrument 1.0 in Patients with Chronic Hepatitis B: A Prospective Study

Ha, Yeonjung; Hwang, Sohyun; Chon, Young Eun; Lee, Joo Ho; Hwang, Seong Gyu

doi:10.3390/jcm8050656

Cited by 7 publications

(9 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[28] The estimates of patients' quality of life were limited as they were not assessed with instruments specific to patients with chronic liver disease. [29] In conclusion, TARE is the more cost-effective DS strategy for patients with HCC exceeding Milan criteria compared to TACE and remains so as long as the number of treatments for DS is at least 1 fewer after TARE than after TACE. This conclusion is robust in multiple subgroup and sensitivity analyses, including CP class, AFP, number of lesions, proportions of successful DS, and eventual transplant.…”

Section: Discussionmentioning

confidence: 88%

See 1 more Smart Citation

Cost-effectiveness analysis of interventional liver-directed therapies for downstaging of HCC before liver transplant

Wu,

Kwong,

Heller

et al. 2023

Liver Transplantation

View full text Add to dashboard Cite

Transarterial chemoembolization (TACE) and transarterial radioembolization (TARE) are the 2 most used modalities for patients with HCC while awaiting liver transplant. The purpose of this study is to perform a cost-effectiveness analysis comparing TACE and TARE for downstaging (DS) patients with HCC. A cost-effectiveness analysis was performed comparing TACE and TARE in DS HCC over a 5-year time horizon from a payer’s perspective. The clinical course, including those who achieved successful DS leading to liver transplant and those who failed DS with possible disease progression, was obtained from the United Network for Organ Sharing. Costs and effectiveness were measured in US dollars and quality-adjusted life years (QALYs). Probabilistic and deterministic sensitivity analyses were performed. TARE achieved a higher effectiveness of 2.51 QALY (TACE: 2.29 QALY) at a higher cost of $172,162 (TACE: $159,706), with the incremental cost-effectiveness ratio of $55,964/QALY, making TARE the more cost-effective strategy. The difference in outcome was equivalent to 104 days (nearly 3.5 months) in compensated cirrhosis state. Probabilistic sensitivity analyses showed that TARE was more cost-effective in 91.69% of 10,000 Monte Carlo simulations. TARE was more effective if greater than 48.2% of patients who received TACE or TARE were successfully downstaged (base case: 74.6% from the pooled analysis of multiple published cohorts). TARE became more cost-effective when the cost of TACE exceeded $4,831 (base case: $12,722) or when the cost of TARE was lower than $43,542 (base case: $30,609). Subgroup analyses identified TARE to be the more cost-effective strategy if the TARE cohort required 1 fewer locoregional therapy than the TACE cohort. TARE is the more cost-effective DS strategy for patients with HCC exceeding Milan criteria compared to TACE.

show abstract

Section: Discussionmentioning

confidence: 88%

“…No specific details were provided based on the dose of radiation or technical approach (lobar versus segmental), which has been shown to predict tumor necrosis in explants 28 . The estimates of patients’ quality of life were limited as they were not assessed with instruments specific to patients with chronic liver disease 29 …”

Section: Discussionmentioning

confidence: 99%

Cost-effectiveness analysis of interventional liver-directed therapies for downstaging of HCC before liver transplant

Wu,

Kwong,

Heller

et al. 2023

Liver Transplantation

View full text Add to dashboard Cite

show abstract

“…In large multi-national studies of patient reported HBV outcomes, poorer health-related quality of life was related to advanced liver disease. The common theme of anxiety is described as advanced liver disease and physical symptoms manifest for those with HBV [ 21 , 24 , 25 ]. Having access to appropriate medical care and treatment could help to alleviate some of the fear and anxiety as well as access to accurate disease-related information to address common misconceptions that exacerbate fear and anxiety.…”

Section: Discussionmentioning

confidence: 99%

Common concerns, barriers to care, and the lived experience of individuals with hepatitis B: a qualitative study

et al. 2021

View full text Add to dashboard Cite

Background An estimated between 257 and 292 million people live with chronic HBV globally. While much is known about the causes, and epidemiology of HBV, little is understood about the quality of life and impact of HBV on those living with the infection. Methods A random sample of HBV-related email queries sent to the Hepatitis B Foundation, a U.S.-based non-profit organization, over a 12-month period in 2018–2019 were retrieved, tabulated, and analyzed qualitatively to highlight information needs and explore the experiences of people living with HBV and their families and loved ones. Codebook development was informed by the literature and through line-by-line reading of a sub-sample of queries. Data analysis was facilitated by NVivo12 software. Data were coded independently by two members of the research team and intercoder reliability was assessed to assure coding accuracy throughout the coding phase. Results A total of 338 queries from people around the globe were identified and analyzed. The analysis revealed three thematic groups: 1) health-specific challenges associated with diagnosis and treatment, 2) emotional needs related to experiences with HBV stigma, discrimination, fear, social isolation, and distress and 3) informational needs related to HBV prevention and transmission, and interpretation of laboratory tests. Conclusions People living with HBV are in need of information to manage their disease and prevent its spread. Analysis of queries uncovered significant misconceptions about HBV transmission and treatment. Additionally, the emotional and psychological impact of an HBV diagnosis on those living with the infection is significant. There is a clear need for patient and community education to expand knowledge and awareness of HBV globally to achieve 2030 WHO HBV elimination goals.

show abstract

“…The common theme of anxiety is described as advanced liver disease and physical symptoms manifest for those with HBV. , 30,27,31 Having access to appropriate medical care and treatment could help to alleviate some of the fear and anxiety as well as access to accurate disease-related information to address common misconceptions that exacerbate fear and anxiety.…”

Section: Discussionmentioning

confidence: 99%

Common Concerns, Barriers to Care, and the Lived Experience of Individuals with Hepatitis B: A Qualitative Study

Freeland

Farrell

Kumar

et al. 2021

Preprint

View full text Add to dashboard Cite

Background & Aims: An estimated between 257 and 292 million people live with chronic HBV globally. While much is known about the causes, and epidemiology of HBV, little is understood about the quality of life and impact of HBV on those living with the infection. Approach and Results: A random sample of HBV-related email queries sent to the Hepatitis B Foundation, a U.S.-based non-profit organization, over a 12-month period in 2018-2019 were retrieved, tabulated, and analyzed qualitatively to highlight information needs and explore the experiences of people living with HBV and their families and loved ones. Codebook development was informed by the literature and through line-by-line reading of a sub-sample of queries. Data analysis was facilitated by NVivo12 software. Data were coded independently by two members of the research team and intercoder reliability was assessed to assure coding accuracy throughout the coding phase. A total of 338 queries from people around the globe were identified and analyzed. The analysis revealed three thematic groups: 1) health-specific challenges associated with diagnosis and treatment, 2) emotional needs related to experiences with HBV stigma, discrimination, fear, social isolation, and distress and 3) informational needs related to HBV prevention and transmission, and interpretation of laboratory tests.Conclusions: People living with HBV are in need of information to manage their disease and prevent its spread. Analysis of queries uncovered significant misconceptions about HBV transmission and treatment. Additionally, the emotional and psychological impact of an HBV diagnosis on those living with the infection is significant. There is a clear need for patient and community education to expand knowledge and awareness of HBV globally to achieve 2030 WHO HBV elimination goals.

show abstract

Validation of the Liver Disease Quality of Life Instrument 1.0 in Patients with Chronic Hepatitis B: A Prospective Study

Cited by 7 publications

References 15 publications

Cost-effectiveness analysis of interventional liver-directed therapies for downstaging of HCC before liver transplant

Cost-effectiveness analysis of interventional liver-directed therapies for downstaging of HCC before liver transplant

Common concerns, barriers to care, and the lived experience of individuals with hepatitis B: a qualitative study

Common Concerns, Barriers to Care, and the Lived Experience of Individuals with Hepatitis B: A Qualitative Study

Contact Info

Product

Resources

About